CClinicalTrials.gg
Active, not recruitingNCT05592002ACCCESSUpdated Sep 5, 2025

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

An interventional study of Genio System in Sleep Apnea, Obstructive, sponsored by Nyxoah S.A.. Active, not recruiting at 16 sites in United States. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Nyxoah S.A. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Study summary

The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.

Read the detailed description

Nyxoah has developed the Genio® 2.1 System with the intention of treating patients with moderate to severe obstructive sleep apnea.

In overview, the System includes an Implantable Stimulator (IS) designed to stimulate the hypoglossal nerve branches (i.e., both the left and the right). The IS does not include a battery but receives energy pulses transmitted by an Activation Chip (AC) which is attached to an adhesive Disposable Patch (DP) and placed on the patient's skin under the chin. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway.

02

Conditions studied

  • Sleep Apnea, Obstructive
03

In context

Sleep Apnea, Obstructive

2,198 studies on the registry are indexed under Sleep Apnea, Obstructive; 470 are open to participants now.

This study's planned enrollment of 124 is above the median of 53 across 1,448 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Nyxoah S.A. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 1. Age from 22 to 75 years (inclusive). Participant cannot be under guardianship, under curatorship or under judicial protection.

    2. Body mass index (BMI) ≤ 32 kg/m2. 3. Positive cricomental space (≥ 0 cm). The cricomental space is the distance between the neck and the bisection of a line from the chin to the cricoid membrane when the head is in a neutral position.

    4. Has either not tolerated, has failed or refused positive airway pressure (PAP) treatments.

    5. Moderate to severe OSA (15≤AHI4≤65 where combined central and mixed AHI\<25% of the total AHI) based on a screening HST and confirmed in Baseline PSG.

    6. Complete concentric collapse at the level of the soft palate based on screening DISE.

    7. Willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits and sleep studies, evaluation procedures and questionnaires for the whole duration of the trial.

Exclusion criteria

  1. Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:

    1. Severe chronic insomnia,
    2. Insufficient sleep syndrome (\<6 hours sleep per night),
    3. Narcolepsy,
    4. Restless legs syndrome,
    5. REM behavior disorder,
    6. Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
    1. Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
    2. Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:

      1. Craniofacial abnormalities narrowing the airway or the implantation site,
      2. Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
      3. Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
      4. Congenital malformations in the airway,
      5. Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
      6. Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
      7. Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
    3. Significant comorbidities that contraindicate surgery or general anesthesia:

      1. Revised Cardiac Risk Index Class III or IV,
      2. Persistent uncontrolled diagnosed hypertension despite medications,
      3. Coagulopathy or required anticoagulant or antiplatelet medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period, Subjects meeting any of the following criteria will be excluded from participation in this study:

    <!-- -->

    1. Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:

      1. Severe chronic insomnia,
      2. Insufficient sleep syndrome (\<6 hours sleep per night),
      3. Narcolepsy,
      4. Restless legs syndrome,
      5. REM behavior disorder,
      6. Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
    2. Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
    3. Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:

      1. Craniofacial abnormalities narrowing the airway or the implantation site,
      2. Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
      3. Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
      4. Congenital malformations in the airway,
      5. Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
      6. Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
      7. Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
    4. Significant comorbidities that contraindicate surgery or general anesthesia:

      1. Revised Cardiac Risk Index Class III or IV,
      2. Persistent uncontrolled diagnosed hypertension despite medications,
      3. Coagulopathy or required anticoagulant medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period,
      4. Degenerative neurological disorder (i.e., Parkinson's disease, Alzheimer's disease),
      5. Acute illness or infection,
      6. Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia in the judgment of the investigator.
    5. Diagnosed psychiatric disease (e.g., psychotic illness, uncontrolled major depression or acute anxiety attacks) that prevents participant compliance with the requirements of the investigational study testing,
    6. Substance or alcohol abuse history within the previous 3 years. Alcohol and substance abuse are defined as follows:

      i. Alcohol: no days with less than 3 or 4 standard drinks for women and men respectively ii. Substance: the use of any substance in an amount unapproved by the investigator or considered illegal. The drugs most commonly abused include cocaine, marijuana, heroin (or substitution treatment), prescription drugs (especially painkillers), methamphetamines, and various other illegal substances.

    7. Life expectancy of less than 12 months.
    8. Prior surgery or treatments that could compromise the effectiveness of the Genio® System:

      1. Airway cancer surgery or radiation,
      2. Mandible or maxilla surgery in the previous 5 years (not counting dental treatments),
      3. Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),
      4. Prior hypoglossal nerve stimulation device implantation.
    9. Has an Active Implantable Medical Device (AIMD) even if the device can be temporarily turned off.
    10. Participation in another clinical study with an active treatment arm.
    11. Plan to become pregnant, currently pregnant, or breastfeeding during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Genio® 2.1 System

    System Component Genio® System 2.1 Implantable Stimulator (IS) Genio® Implantable Stimulator External Stimulator (ES) Genio® External Stimulator Disposable Patch (DP) Genio® Disposable Patch Activation Chip (AC) Genio® Activation Chip (AC) Model #2364 Charging Unit (CU) Genio® Charging Unit (CU) Model #2238 Sleep Lab Application Genio® Sleep Lab Application Smartphone Application (optional) Genio® Smartphone Application

    Device: Genio System

Interventions

  • DeviceGenio System

    The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.

    Also known as: Genio System 2.0

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    The effectiveness endpoint of the study is assessed through the reduction in the severity of OSA over a period of 12 months post-implant. Primary effectiveness endpoint: percentage of responders based on a change in apnea-hypopnea index (AHI4) and oxygen desaturation index (ODI4) at 12 months post-activation. A responder is defined as any subject with a reduction of 50% in AHI4 from Baseline and a remaining AHI4 \< 20 events/hour (aka "Sher Criteria"), AND 25% in ODI4 from Baseline.

    Time frame: The duration of the study is expected to be approximately 4.5 years.

07

Study locations

16 sites
  • Colorado ENT & Allergy
    Colorado Springs, Colorado 80923, United States
  • ENT and Allergy Associates of Florida, LLC
    Boca Raton, Florida 33487, United States
  • University of Miami
    Miami, Florida 33136, United States
  • PharmaDev Clinical Research Institute,
    Miami, Florida 33176, United States
  • University of South Florida
    Tampa, Florida 33620, United States
  • Center for ENT and Allergy, PC Ascension Medical Group
    Carmel, Indiana 46032, United States
  • University of Iowa Institute for Clinical & Translational Science
    Iowa City, Iowa 52242, United States
  • University of Kansas
    Kansas City, Kansas 66160, United States
  • Massachusetts Eye & Ear
    Boston, Massachusetts 02114, United States
  • University of Rochester
    Rochester, New York 14627, United States
  • Hospital of the University Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Department of Otolaryngology
    Philadelphia, Pennsylvania 19107, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05592002
Lead sponsor
Nyxoah S.A.
Collaborators
Nyxoah Inc.
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Dec 28, 2022
Primary completion
Sep 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 5, 2025

Study contacts

Jey Subarroyan, PhD
study director · Nyxoah S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion